268 related articles for article (PubMed ID: 29634138)
21. [Characterization of ESBL-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urine of nonhospitalized patients in the Zagreb region].
Marijan T; Plecko V; Vranes J; Dzepina AM; Bedenić B; Kalenić S
Med Glas (Zenica); 2010 Feb; 7(1):46-53. PubMed ID: 20387724
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
Demir T; Buyukguclu T
Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
[TBL] [Abstract][Full Text] [Related]
23. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
[TBL] [Abstract][Full Text] [Related]
24. Resistance in gram-negative bacteria: enterobacteriaceae.
Paterson DL
Am J Med; 2006 Jun; 119(6 Suppl 1):S20-8; discussion S62-70. PubMed ID: 16735147
[TBL] [Abstract][Full Text] [Related]
25. Occurrence of ESBL & Amp-C beta-lactamases & susceptibility to newer antimicrobial agents in complicated UTI.
Taneja N; Rao P; Arora J; Dogra A
Indian J Med Res; 2008 Jan; 127(1):85-8. PubMed ID: 18316858
[TBL] [Abstract][Full Text] [Related]
26. [Extended-spectrum beta-lactamase in Klebsiella pneumoniae and Escherichia coli isolates].
Xiong Z; Zhu D; Zhang Y; Wang F
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(21):1476-9. PubMed ID: 12509910
[TBL] [Abstract][Full Text] [Related]
27. Bacterial profile and drug susceptibility pattern of urinary tract infection in pregnant women at Tikur Anbessa Specialized Hospital Addis Ababa, Ethiopia.
Assefa A; Asrat D; Woldeamanuel Y; G/Hiwot Y; Abdella A; Melesse T
Ethiop Med J; 2008 Jul; 46(3):227-35. PubMed ID: 19271386
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
Azap OK; Arslan H; Serefhanoğlu K; Colakoğlu S; Erdoğan H; Timurkaynak F; Senger SS
Clin Microbiol Infect; 2010 Feb; 16(2):147-51. PubMed ID: 19689464
[TBL] [Abstract][Full Text] [Related]
29. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
Akyar I
Mikrobiyol Bul; 2008 Oct; 42(4):713-5. PubMed ID: 19149097
[TBL] [Abstract][Full Text] [Related]
30. Underlying mechanisms of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli isolates at a tertiary care centre in Lebanon: role of OXA-48 and NDM-1 carbapenemases.
Baroud M; Dandache I; Araj GF; Wakim R; Kanj S; Kanafani Z; Khairallah M; Sabra A; Shehab M; Dbaibo G; Matar GM
Int J Antimicrob Agents; 2013 Jan; 41(1):75-9. PubMed ID: 23142087
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
32. [The presence of extended spectrum beta-lactamase, KPC-type carbapenemase and plasmid-mediated AmpC beta-lactamase in E.coli and K.pneumoniae strains isolated from blood cultures].
Baykal A; Cöplü N; Simşek H; Esen B; Gür D
Mikrobiyol Bul; 2012 Apr; 46(2):159-69. PubMed ID: 22639305
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases.
Calbo E; Romaní V; Xercavins M; Gómez L; Vidal CG; Quintana S; Vila J; Garau J
J Antimicrob Chemother; 2006 Apr; 57(4):780-3. PubMed ID: 16492721
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic confirmation of extended-spectrum B-lactamases (ESBL) in clinical isolates of Escherichia coli and Klebsiella pneumoniae at the San Juan Veterans Affairs Medical Center.
Del Carmen Rodríguez M; Vera DE; Ramírez-Ronda CH; Saavedra S
P R Health Sci J; 2004 Sep; 23(3):207-15. PubMed ID: 15631176
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections.
Wu YH; Chen PL; Hung YP; Ko WC
J Microbiol Immunol Infect; 2014 Jun; 47(3):197-203. PubMed ID: 23063776
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
Kader AA; Kumar AK
Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
[TBL] [Abstract][Full Text] [Related]
37. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
[TBL] [Abstract][Full Text] [Related]
38. [Five years follow-up of infections with extended-spectrum beta-lactamase producing enterobacteriaceae].
Fouquet M; Morange V; Bruyère F
Prog Urol; 2012 Jan; 22(1):17-21. PubMed ID: 22196001
[TBL] [Abstract][Full Text] [Related]
39. Antimicrobial resistance among bacteria isolated from urinary tract infections in females in Namibia, 2016-2017.
Haindongo EH; Funtua B; Singu B; Hedimbi M; Kalemeera F; Hamman J; Vainio O; Hakanen AJ; Vuopio J
Antimicrob Resist Infect Control; 2022 Feb; 11(1):33. PubMed ID: 35151360
[TBL] [Abstract][Full Text] [Related]
40. Emergence of Metallo-β-Lactamases and OXA-48 Carbapenemase Producing Gram-Negative Bacteria in Hospital Wastewater in Algeria: A Potential Dissemination Pathway Into the Environment.
Cherak Z; Loucif L; Moussi A; Bendjama E; Benbouza A; Rolain JM
Microb Drug Resist; 2022 Jan; 28(1):23-30. PubMed ID: 34314638
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
